You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Screens for Novel Agonists/Antagonists of Endocrine Fibroblast Growth Factors
SBC: AGAVE BIOSYSTEMS INC. Topic: NIDDKDESCRIPTION (provided by applicant): Agave BioSystems and Professor Makoto Kuro-o at the University of Texas Southwestern Medical Center are proposing a collaborative effort to screen for novel small molecules acting as agonists or antagonists of the Klotho and Klotho- dependent endocrine Fibroblast Growth Factors. The expected outcome of this Phase I effort will be the validation of a high-throug ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Development of Novel LANCL2-based Anti-diabetic Compounds
SBC: Biotherapeutics, Inc. Topic: NIDDKDESCRIPTION (provided by applicant): About 28.3 million Americans have type II diabetes (T2D) and over 40.1% of middle-aged adults have prediabetes, a condition characterized by impaired glucose tolerance and insulin resistance. Current antidiabetic medications are effective in improving insulin sensitivity, but their chronic administration has significant side effects suc as cardiovascular compli ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Preclinical Efficacy And Safety Evaluation Of Graphene Nanoparticle-based Magneti
SBC: Theragnostic Technologies Inc. Topic: NIDDKAbstract This STTR phase 1 proposal investigates the safety and efficacy of a novel high-performance carbon nanostructure-based magnetic resonance imaging (MRI) contrast agent for the imaging and monitoring of patients with renal failure. Every year, in the US, approximately 20 million people are treated for mild to severe renal failure. A significant number of cases (greater than 50%) related to ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Enhanced bioscavenger for medical countermeasures against organophosphorus agents
SBC: Luna Innovations Incorporated Topic: NIEHSDESCRIPTION (provided by applicant): Counteracting the threat of intoxication by organophosphorus nerve agents (OP's) is an important mission for homeland security as well as for treating workers exposed to pesticides. OP's act on acetylcholinesterase to prevent synaptic inactivation, thereby leading to immobilization and death on sustained application. Currently, the most promising stra ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
In-situ, real-time oxygen sensor to monitor the long-term efficacy of aerobicall
SBC: ChromoSense LLC Topic: NIEHSDESCRIPTION (provided by applicant): Groundwater and soil contamination has been associated with higher incidence of birth defects and cancer. Monitored natural attenuation of contaminants via biodegradation has proven effective in lowering contaminant levels, but these processes depend critically on dissolved oxygen levels. This project proposes to develop a robust oxygen sensor compound with che ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
A Thermo-responsive Biopharmaceutical to Enhance the Tear Production of Lacritin
SBC: EYERX RESEARCH, INC. Topic: NEIProject Summary/Abstract Ocular pharmaceuticals predominantly use the topical route of administration, which involves a number of benefits and limitations when compared to systemic drug routes. A major limitation of the ocular topical route is the rapid loss of drug via tearing and nasolacrimal drainage, requiring the use of frequent dosing and high drug concentrations that then create formulation ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Zonular Capture Accommodative-Disaccommodative Intraocular Lens System
SBC: Z Lens LLC Topic: NEIDESCRIPTION (provided by applicant): We are developing an accommodative - disaccommodative intraocular lens implant (ADIOL) system based on a novel concept of capturing zonular tension and transmitting it unimpeded to a dynamically position intraocular lens system. This is made possible by a zonular capture haptic (ZCH) apparatus. This apparatus lends itself equally well to several possible combin ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Nanoparticle scavengers for medical countermeasures against mycotoxin
SBC: Luna Innovations Incorporated Topic: NIGMSDESCRIPTION (provided by applicant): Mycotoxin is naturally occurring and is a toxic small molecule produced by fungi. These fungal toxins are representative of a large number of lipophilic agents that pose significant acute and chronic dangers to militarycombatants as potential warfare agents. There are many examples of mycotoxins, some more acutely potent than others. Mycotoxin is classified as ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Application of CDX-MDM in Pre-Clinical Model of Murine Pulmonary Emphysema
SBC: Covenant Therapeutics LLC Topic: NHLBIDESCRIPTION (provided by applicant): The objective of this proposal is to exploit a newly discovered anti-inflammatory function involving the aminopeptidase activity of the leukotriene A4 hydrolase for the treatment of pulmonary emphysema. The leukotrieneA4 hydrolase is a dual-functioning enzyme with dichotomously opposing functions. As an epoxide hydrolase, it catalyzes the conversion of leukotri ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Innovative Use of the Noom Monitor Mobile Application for CBT-GSH in Binge Eaters
SBC: Noom, Inc. Topic: NIMHDESCRIPTION (provided by applicant): Bulimia nervosa and binge eating disorder are marked by significant levels of impairment and psychiatric comorbidity, affecting approximately 5-7% of the US population. Guided self-help cognitive behavioral (CBT-GSH) therapy has been show to be an effective treatment to reduce binge eating for patient with both disorders. However, there is limited uptake among ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health